Akebia Therapeutics Inc
AKBA
NASDAQ
Biotechnology
$0.87
USD
0.00 (+0.37%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $240.97M
Volume 2.1M
Revenue
$219.06M
TTM
+7.5%
YoY
Gross Margin
80%
TTM
+7.0%
YoY
Net Income
$-29.67M
TTM
+18.7%
YoY
Operating Cash Flow
$41.55M
TTM
+1829.2%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 62.5 | 58.8 | 57.6 | 53.5 | 49.1 |
YoY Growth | +43.1% | +57.0% | +23.9% | -6.6% | -21.4% |
Cost of Revenue | 9.9 | 9.4 | 12.5 | 12.3 | 10.4 |
Gross Profit | 52.6 | 49.4 | 45.1 | 41.3 | 38.7 |
Selling, General & Administrative | 26.6 | 29.1 | 26.1 | 30.4 | 28.2 |
Other Operating Expenses | 0.9 | 0.9 | 0.9 | 0.7 | 2.8 |
Total Operating Expenses | 38.5 | 44.9 | 53.6 | 46.0 | 45.0 |
Operating Income | 14.1 | 4.4 | -8.6 | -4.7 | -6.3 |
EBITDA | 14.4 | 4.8 | -8.2 | -4.4 | -3.8 |
Other Income / Expense | -7.0 | 1.5 | 2.1 | 0.5 | 0.6 |
Total Other Income / Expense | -13.8 | -3.3 | -2.7 | -4.2 | -2.5 |
Income Before Income Taxes | 0.2 | 1.2 | -11.2 | -8.9 | -8.8 |
Income Taxes | 0.0 | 0.6 | 1.0 | 0.1 | 0.1 |
Net Income | 0.2 | 0.5 | -12.2 | -9.1 | -8.9 |
Consolidated Net Income / Loss | 0.2 | 0.5 | -12.2 | -9.1 | -8.9 |
Net Income Attributable to Common Shareholders | 0.2 | 0.5 | -12.2 | -9.1 | -8.9 |
Basic EPS | $0.00 | $0.00 | -$0.05 | -$0.03 | -$0.03 |
Diluted EPS | $0.00 | $0.00 | -$0.05 | -$0.03 | -$0.03 |
Basic Shares Outstanding | 262.6M | 264.8M | 265.8M | 267.0M | 269.6M |
Diluted Shares Outstanding | 271.1M | 274.4M | 241.6M | 267.0M | 269.6M |